Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

Kurishima,Koichi; Satoh,Hiroaki; Kaburagi,Takayuki; Nishimura,Yoshihiro; Shinohara,Yoko; Inagaki,Masaharu; Endo,Takeo; Saito,Takefumi; Hayashihara,Kenji; Hizawa,Nobuyuki; Nakamura,Hiroyuki; Nawa,Takeshi; Kagohashi,Katsunori; Kishi,Koji; Ishikawa,Hiroichi; Ichimura,Hideo; Hashimoto,Toshio; Sato,Yukio; Sakai,Mitsuaki; Kamiyama,Koichi; Matsumura,Takeshi; Unoura,Koji; Fukuoka,Toshihiko; Uchiumi,Keiko; Nomura,Akihiro; Furukawa,Kinya

doi:10.3892/mco.2013.154

September-October 2013 Volume 1 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-October 2013 Volume 1 Issue 5

Full Size Image

Article

Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

Authors:
- Koichi Kurishima
- Hiroaki Satoh
- Takayuki Kaburagi
- Yoshihiro Nishimura
- Yoko Shinohara
- Masaharu Inagaki
- Takeo Endo
- Takefumi Saito
- Kenji Hayashihara
- Nobuyuki Hizawa
- Hiroyuki Nakamura
- Takeshi Nawa
- Katsunori Kagohashi
- Koji Kishi
- Hiroichi Ishikawa
- Hideo Ichimura
- Toshio Hashimoto
- Yukio Sato
- Mitsuaki Sakai
- Koichi Kamiyama
- Takeshi Matsumura
- Koji Unoura
- Toshihiko Fukuoka
- Keiko Uchiumi
- Akihiro Nomura
- Kinya Furukawa
View Affiliations / Copyright

Affiliations: Tsukuba University Hospital, Tsukuba, Ibaraki 305-8576, Japan, Mito Medical Center, University of Tsukuba, Mito, Ibaraki 310-0015, Japan, Ibaraki Prefectural Central Hospital and Regional Cancer Center, Kasama, Ibaraki 309-1793, Japan, Mito Chuo Hospital, Mito, Ibaraki 311-1135, Japan, Tsuchiura Kyodo General Hospital and Regional Cancer Center, Tsuchiura, Ibaraki 300-0053, Japan, National Hospital Organisation, Mito Medical Center Hospital, Mito, Ibaraki 311-3193, Japan, Ibaraki Higashi National Hospital, Tokai, Ibaraki 319-1113, Japan, Tokyo Medical University, Ibaraki Medical Center Hospital, Ami, Ibaraki 300-0395, Japan, Hitachi General Hospital, Hitachi, Ibaraki 317-0077, Japan, Tsukuba Medical Center Hospital and Regional Cancer Center, Tsukuba, Ibaraki 305-8558, Japan, Mito Saiseikai General Hospital, Mito, Ibaraki 311-4198, Japan, Tsukuba Memorial Hospital, Tsukuba, Ibaraki 300-2622, Japan, Ibaraki Seinan Medical Center Hospital, Sakai, Osaka 306-0433, Japan, JA Toride Medical Center, Toride, Ibaraki 302-0022, Japan
Pages: 828-832
|
Published online on: July 23, 2013

https://doi.org/10.3892/mco.2013.154
Expand metrics +

Abstract

The incidence and mortality of lung cancer have increased worldwide over the last decades, with an observed increased incidence particularly among elderly populations. It has not yet been determined whether erlotinib therapy exhibits the same efficacy and safety in elderly and younger patients with non‑small‑cell lung cancer (NSCLC). The aim of this retrospective subgroup analysis of data from a population‑based observational study was to assess the efficacy and safety of erlotinib in an elderly (≥75 years, n=74) and a younger group of patients (<75 years, n=233) who received treatment for NSCLC. The time to treatment failure was similar in the elderly [median, 62 days; 95% confidence interval (95% CI): 44‑80 days] compared with the younger group (median, 46 days; 95% CI: 35‑53 days) (P=0.2475). The overall survival did not differ between the elderly and younger groups (median, 170 days; 95% CI: 142‑239 days vs. median, 146 days; 95% CI: 114‑185 days, respectively) (P=0.7642). The adverse events did not differ in incidence between the groups and were manageable, regardless of age. Among the NSCLC patients receiving erlotinib treatment, the outcomes of the elderly (≥75 years) and younger (<75 years) groups of patients were similar in our population‑based observational study.

View Figures

View References

1	Bilello KS, Murin S and Matthay RA: Epidemiology, etiology, and prevention of lung cancer. Clin Chest Med. 23:1–25. 2002. View Article : Google Scholar : PubMed/NCBI
2	Gabrielson E: Worldwide trends in lung cancer pathology. Respirology. 11:533–538. 2006. View Article : Google Scholar : PubMed/NCBI
3	Chen YM, Tsai CM, Fan WC, et al: Phase II randomized trial of erlotinib or vinorelbine in chemonaive, advanced, non-small cell lung cancer patients aged 70 years or older. J Thorac Oncol. 7:412–418. 2012.PubMed/NCBI
4	Platania M, Agustoni F, Formisano B, et al: Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Target Oncol. 6:181–186. 2011. View Article : Google Scholar : PubMed/NCBI
5	Inoue A, Kobayashi K, Usui K, et al; North East Japan Gefitinib Study Group. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol. 27:1394–1400. 2009. View Article : Google Scholar : PubMed/NCBI
6	Jackman DM, Yeap BY, Lindeman NI, et al: Phase II clinical trial of chemotherapy-naive patients > or=70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol. 25:760–766. 2007.
7	Maemondo M, Minegishi Y, Inoue A, et al: First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study. J Thorac Oncol. 7:1417–1422. 2012. View Article : Google Scholar : PubMed/NCBI
8	Reck M, Mok T, Wolf J, et al: Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opin Drug Saf. 10:147–157. 2011. View Article : Google Scholar : PubMed/NCBI
9	Bezjak A, Tu D, Seymour L, et al; National Cancer Institute of Canada Clinical Trials Group Study BR.21. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 24:3831–3837. 2006. View Article : Google Scholar
10	Kubota K, Nishiwaki Y, Tamura T, et al: Efficacy and safety of erlotinib as monotherapy for Japanese patients with advanced non-small-cell lung cancer: a phase II study. J Thoracic Oncol. 3:1439–1445. 2008. View Article : Google Scholar : PubMed/NCBI
11	Pirker R, Su W, Rooneem R, et al: Clinical outcome with erlotinib in relation to biomarker status: analysis from the open-label TRUST study in advanced non-small-cell lung cancer (NSCLC). Ann Oncol. 19(Suppl 8): 265P2008.
12	Massuti B, Moran T, Porta R, et al: Multicenter prospective trial of customized erlotinib for advanced non-small-cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Final results of the Spanish Lung Cancer Group (SLCG) trial. J Clin Oncol. 27(Suppl): abstract 80232009.
13	Cappuzzo F, Ciuleanu T, Stelmakh L, et al: SATURN: A double-blind, randomized, phase III study of maintenance erlotinib vs. placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol. 27(Suppl): abstract 80012009.
14	Kaburagi T, Satoh H, Hayashihara K, et al: Observational study on efficacy and safety of erlotinib in patients with non-small-cell lung cancer in Ibaraki, Japan. Oncol Lett. 5:435–439. 2013.PubMed/NCBI
15	Ardizzoni A and Tiseo M: Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). J Chemother. 16(Suppl 4): 104–107. 2004. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Erlotinib for elderly patients with non‑small‑cell lung cancer: Subset analysis from a population‑based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles